胰腺癌是一种极为凶险、高度恶性的消化道肿瘤。随着外科技术的进步和新辅助治疗引入，如何准确评价胰腺癌新辅助治疗(Neoadjuvant Therapy,NAT)疗效指导下一步准确有效的治疗已成为胰腺癌诊治的关键。目前研究表明传统影像学因无法准确区分NAT后肿块内的肿瘤组织和纤维组织，而高估治疗后的肿瘤大小和T分期。影像组学可获取大量客观定量的肿瘤特征，其在直肠癌等恶性肿瘤中对NAT疗效及预后评估显示了优良的应用前景。目前国内外尚无利用影像组学进行胰腺癌NAT的疗效评估及预后的研究。本研究以美国病理学会CAP分级为金标准，基于影像组学方法，利用CT图像对胰腺癌NAT后的疗效进行影像定量评估，并综合传统影像及临床指标，建立更优化的疗效综合评估模型并前瞻性地验证其准确性、有效性，为胰腺癌的诊治提供实用化的影像工具。

Pancreatic adenocarcinoma is a highly pernicious and malignant digestive tract tumor. With the progress of surgical technology and the introduction of new adjuvant therapy, how to evaluate the curative effect of Neoadjuvant Therapy (NAT) and guide more accurate and effective treatment in the next step has become the key to the diagnosis and treatment of pancreatic cancer. The current research shows that traditional imaging can not accurately distinguish the tumor tissue and fibrous tissue in the lesion after NAT, and overestimate the size of the tumor and the T staging after treatment. Radiomics can obtain a large number of objective and quantitative tumor characteristics. It shows excellent application prospects in the treatment of NAT and prognosis in rectal cancer and other malignant tumors. At present, there is no study on the therapeutic evaluation and prognosis of pancreatic cancer after NAT at home and abroad. Therefore, the purpose of this study is to using CT 3D imaging and based on radiomics to evaluate the curative effect of pancreatic cancer quantitatively after NAT, referred to the College of American Pathologists (College CAP of American Pathologists) classification as the gold standard. Then combined with traditional imaging and clinical evaluating indicator to establish a more optimized comprehensive evaluation model of curative effect and prospectively verify its accuracy and effectiveness. It will provide a practical imaging tool for the diagnosis and treatment of pancreatic cancer.